Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dishman Carbogen Amcis has informed that the meeting of the Board of Directors of the Company is scheduled on 16/01/2020 to consider a proposal for buy-back of equity shares of the Company; to consider a proposal of setting up of a Share Based Employee Benefit Scheme. The outcome of the Board Meeting will be disseminated to the stock exchanges after conclusion of the Board meeting on 16th January, 2020. Further, as intimated vide letter dated 31st December, 2019, the trading window for dealing in securities/shares of the Company has already been closed and shall remain closed for all the Directors(s), Designated Persons and their relatives till the 48 hours after the announcement of the un-audited financial results of the Company for the quarter ended 31st December, 2019.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: